Targeting of breast metastases using a viral gene vector with tumour-selective transcription

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1627-1635

  Rajendran, Simon ^a,b   Collins, Sara ^a   Van Pijkeren, Jan P ^a   O'Hanlon, Deirdre ^b   O'Sullivan, Gerald C ^a   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b SOUTH INFIRMARY VICTORIA UNIVERSITY HOSPITAL   (Ireland)

Author keywords

AAV; Bioluminescence; Breast cancer; CXCR4; Gene therapy

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER GENE THERAPY; CELL STRAIN MCF 7; CYTOMEGALOVIRUS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; DEPENDOVIRUS; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; RECEPTORS, CXCR4; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 79958171742     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lacey JV Jr., Devesa SS and Brinton LA: Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 39(2-3): 82-88, 2002. (Pubitemid 34260479)
2. Jooss K, Ertl HC and Wilson JM: Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 72(4): 2945-2954, 1998. (Pubitemid 28175532)
3. The Journal of Gene Medicine. Gene Therapy Clinical Trials Worldwide 2011 [Last accessed 2011 Mar 25]; Available from: http://www.wiley.co.uk/ genetherapy/clinical/.
4. Aiuti A, Bachoud-Levi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, Gao G, High KA, Leen AM, Lemoine NR, McNeish IA, Meneguzzi G, Peschanski M, Roncarolo MG, Strayer DS, Tuszynski MH, Waxman DJ and Wilson JM: Progress and prospects: gene therapy clinical trials (part 2). Gene Ther 14(22): 1555-1563, 2007.
5. Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD, Powell S, Keller T, McMurray M, Labelle A, Nagy D, Vargas JA, Zhou S, Couto LB and Pierce GF: Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108(1): 107-115, 2006. (Pubitemid 43990618)
6. Mueller C and Flotte TR: Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15(11): 858-863, 2008. (Pubitemid 351712619)
7. Buhles A, Collins SA, van Pijkeren JP, Rajendran S, Miles M, O'Sullivan GC, O'Hanlon DM and Tangney M: Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. Genet Vaccines Ther 7 5, 2009.
8. Bartlett JS, Kleinschmidt J, Boucher RC and Samulski RJ: Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 17(2): 181-186, 1999. (Pubitemid 29072544)
9. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC and Tangney M: Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 8(2): 66-78, 2008.
10. Flotte TR: Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 11(10): 805-810, 2004.
11. Wu Z, Asokan A and Samulski RJ: Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14(3): 316-327, 2006. (Pubitemid 44184972)
12. Collins SA, Buhles A, Scallan MF, Harrison PT, O'Hanlon DM, O'Sullivan GC and Tangney M: AAV2-mediated in vivo immune gene therapy of solid tumours. Genet Vaccines Ther 8 8, 2010.
13. Nettelbeck DM, Jerome V and Muller R: Gene therapy: designer promoters for tumour targeting. Trends Genet 16(4): 174-181, 2000. (Pubitemid 30169153)
14. Robson T and Hirst DG: Transcriptional Targeting in Cancer Gene Therapy. J Biomed Biotechnol 2003(2): 110-137, 2003.
15. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, 3rd, Yamamoto M, Alvarez RD and Curiel DT: Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther 11(7): 645-648, 2004. (Pubitemid 38455983)
16. Kato M, Kitayama J, Kazama S and Nagawa H: Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5(5): R144-150, 2003.
17. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824): 50-56, 2001. (Pubitemid 32225831)
18. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D and Luker GD: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64(23): 8604-8612, 2004. (Pubitemid 39552073)
19. Kulbe H, Levinson NR, Balkwill F and Wilson JL: The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol 48(5-6): 489-496, 2004. (Pubitemid 39360399)
20. Rajendran S, Salwa S, Gao X, Tabirca S, O'Hanlon D, O'Sullivan GC and Tangney M: Murine bioluminescent hepatic tumour model. J Vis Exp 41: 2010.
21. Cashman JP, Larkin JO, Casey G, Whelan MC, Collins C, Aarons S, Tangney M and O'Sullivan GC: Immune gene therapy as a neoadjuvant to surgical excision to control metastatic cancers. Cancer Lett 2008.
22. Kasuya H, Kuruppu DK, Donahue JM, Choi EW, Kawasaki H and Tanabe KK: Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies. Cancer Res 65(9): 3823-3827, 2005. (Pubitemid 40616362)
23. Rajendran S, O'Hanlon D, Morrissey D, O'Donovan T, O'Sullivan GC and Tangney M: Preclinical evaluation of gene delivery methods for the treatment of loco-regional disease in breast cancer. Exp Biol Med (Maywood) 236 2011.
24. Rajendran S, Salwa S, Gao X, Tabirca S, O'Hanlon D, O'Sullivan GC and Tangney M: Ex vivo culture of patient tissue & examination of gene delivery. J Vis Exp 46: 2010.
25. van Pijkeren JP, Morrissey D, Monk IR, Cronin M, Rajendran S, O'Sullivan GC, Gahan CG and Tangney M: A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther 21(4): 405-416, 2010.
26. Al-Dosari M, Zhang G, Knapp JE and Liu D: Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. Biochem Biophys Res Commun 339(2): 673-678, 2006. (Pubitemid 41739720)
27. Di Ianni M, Terenzi A, Perruccio K, Ciurnelli R, Lucheroni F, Benedetti R, Martelli MF and Tabilio A: 5-Azacytidine prevents transgene methylation in vivo. Gene Ther 6(4): 703-707, 1999.
28. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P and Rubanyi GM: Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 6(4): 395-404, 2004. (Pubitemid 40228056)
29. Graham T, Mcintosh J, Work LM, Nathwani A and Baker AH: Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genet Vaccines Ther 69, 2008.
30. Teschendorf C, Emons B, Muzyczka N, Graeven U and Schmieget W: Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells. Anticancer Res 30(6): 1931-1935, 2010.